|
|
-
Pat Tallungan, President of the Children's Neuroblastoma Cancer Foundation, presents the introduction to the 2007 Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference June 29, 2007 in Chicago, Il. Read More
|
-
Susan L. Cohn, M.D., Director of Clinical Research, Pediatric Hematology/Oncology at the University of Chicago presents an overview of neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference Read More
|
-
Dr. Peter Adamson, Chief, Division of Clinical Pharmacology and Therapeutics
Director, Experimental Therapeutics in Oncology, The Children’s Hospital of Philadelphia provides an overview of the clinical trial process. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007. Read More
|
-
Dr. Kate Matthay, Division Chief, Pediatric Hematology/Oncology, UCSF and Leader, NANT Consortium presents current NANT protocols, study rationale, and information regarding the NANT and phase 1 trials. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007. Read More
|
-
James G. Gurney, Ph.D. University of Minnesota, provided an overview of his long-term survivor study issues for children with neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007 before his COG article on this subject was published. The reference to the published article is "Hearing Loss, Quality of Life, and Academic Problems in Long-term Neuroblastoma Survivors: A Report From the Children's Oncology Group.", PEDIATRICS Vol. 120 No. 5 November 2007, pp. e1229-e1236 (doi:10.1542/peds.2007-0178) Read More
|
-
Stephen A. Sands, Psy.D. is an Assistant Professor in Pediatrics and Psychiatry at the Columbia University Medical Center. He also serves as the Director of the Valerie Fund Psycho-Social Program at the Herbert Irving Child and Adolescent Oncology Center. During this discussion he provides a historical review of the literature relating to the neurophsycological late effects from treatment of neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007. Read More
|
-
Dr. Patrick Reynolds, MD PhD, Director, Developmental Therapeutics Program,
USC / CHLA Institute for Pediatric Clinical Research provides an overview of the neuroblastoma research process to help the public understand research data and how it should be interpreted. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007. Read More
|
-
Heidi V. Russell, M.D. Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine and study chair of the NANT trial “A Phase I Study of Zoledronic Acid (Zometa) with Cyclophosphamide in Children with Recurrent/Refractory Neuroblastoma and Cortical Bone Involvement.” In this presentation she discusses bone metastases and Zoledronic Acid. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 29, 2007. Read More
|
-
Giselle Sholler, M.D., Assistant Professor of Pediatrics, Vermont Cancer Center, University of Vermont, presents her preclinical and clinical data regarding Nifurtimox and its potential use in the treatment of neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007.
Read More
|
-
Wendy Mitchell M.D., Neurology Division, Childrens Hospital Los Angeles discusses Opsoclonus-Ataxia Syndrome and its relationship to neuroblastoma. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007. Read More
|
-
Clare Twist, M.D., Associate Professor, Department of Pediatrics – Hematology / Oncology, Stanford School of Medicine. She is the Study Chair for the current COG Phase III Study for the treatment of children with Intermediate Risk Neuroblastoma. I am also the Principal Investigator at Stanford for the New Advances in Neuroblastoma (NANT) Consortium. IN this video she discusses intermediate risk neuroblastoma and its treatment. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007. Read More
|
-
Stephan A. Grupp, MD, PhD, Attending physician; Medical Director, Stem Cell Laboratory, Children’s Hospital of Philadelphia presents the upcoming COG phase III transplant study and discusses various transplant related research. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblastoma Conference on June 30, 2007. Read More
|
-
Erik Ludwinski shares his story about his journey through the world of neuroblastoma. Read More
|
-
Molly Hollway, Neuroblastoma Stage III Cancer Survivor Read More
|
-
Mark Dungan provides an overview of Lunch for Life and other programs for the CNCF. Pat Tallungan thanks all of the oncologists and families for their participation. Read More
|
|
|